Collectively, these data suggest that L72-FSY and its long-acting form are superior to WT-IL-2, can selectively induce Tregs in pristane-induced lupus mice, and are more effective in mitigating inflammatory diseases such as SLE and GvHD. The gene discussed is IL2; the disease is systemic lupus erythematosus.